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the 1992 medical drama ‘Lorenzo’s Oil’, directed by George Miller, is at the same time a tragic and uplifting movie which deals with one of the lesser known diseases, 
adrenoleukodystrophy (ALD), which forms part of a subset of 
diseases of interest to the chemical pathologist. The movie follows 
the quest and struggle of Michaela and Augusto Odone to save 
their very own child, Lorenzo, who is found to have this rare 
condition. The events narrated in this movie are based on a true 
story, albeit with some alterations made for a movie adaptation. 
Adrenoleukodystrophy is an X-linked disorder, hence 
primarily affecting males, due to a mutation in the ABCD1 
gene. This gene encodes a protein in the peroxisomal 
membrane which is responsible for very long chain fatty acid 
(VLCFAs) transmembrane transport. In this condition we 
find elevated levels of VLCFAs. Over the years this disease 
has also been referred to as Siemerling-Creutzfeld disease, 
bronzed Schilder’s disease, encephalitis periaxialis diffusa, 
melanodermic type of leukodystrophy, as well as other 
nomenclature variations that were historically applied. The 
clinical spectrum may vary significantly, hence making 
diagnosis more difficult. Males may range from having just 
adrenocortical insufficiency, adrenomyeloneuropathy, or the 
childhood cerebral form, for example.1-7 This last form of the 
disease is the one illustrated in the film. 
Lorenzo is initially depicted in the movie as a bright and 
vivacious young boy. The very first indication in the film 
that something is amiss is when the teacher points out to his 
mother that he is throwing tantrums at school and having 
‘disturbed behavior’. One of the teachers even recommends he 
receives special education classes, which his mother insists will 
be provided at home. In later incidents he falls off his bike, and 
also falls when reaching out for a decoration on the Christmas 
tree. The constellation of events leads his parents to seek 
medical advice. Initial investigations revealed a normal CT 
scan and EEG and no gross visible neurological abnormality. 
Later on his mother finds him listening to very loud music 
and it is discovered that he has hearing impairment. Again, 
after referral to the appropriate medical specialist, an 
auditory processing difficulty is confirmed. Further inpatient 
investigations included tuning fork testing for conductive 
and sensorineural hearing loss, fundoscopy and further 
Cutterguide: No  Printing Process: Offset 
GD: AM 37825
Size: 210 x 297 mm (A4)  Pages: 1  Colors: C M Y K (4 Colors)
Native File: Indesign CC Windows  Generated in: Acrobat Distiller 11
References:
1. Anthony R. White et al. Augmentin® amoxicillin/clavulanate) in the treatment of community-acquired respiratory 
tract infection: a review of the continuing development of an innovative antimicrobial agent Journal of Antimicrobial 
Chemotherapy (2004) 53, Suppl. S1, i3–i20. 
2. Gilbert DN, et al. Sanford guide to Antimicrobial Therapy v.3.11 – last updated March 11, 2014. Sperryville; Antimicrobial 
Therapy, Inc. 2014.
3. Lieberthal AS et al. The Diagnosis and Management of Acute Otitis Media. Pediatrics. 2013; 131; e964 Epub 2013 Feb 25. 
4. Augmentin ES Summary of Product Characteristics, May 2015. 
Spreading infectious energy!
Prepared: November 2016    Job No: MLT_GIB/AES/0001/15(3) 
For more information and dosing instructions:
www.hcp.gsk.com.mt/products/list/augmentin.html
Amoxicillin/Clavulanate Potassium
Powder for oral suspension
✓ Provides extended antibacterial 
coverage to include the most penicillin-
resistant strains.1
✓ Recommended by leading Guidelines as 
first line treatment in AOM.2,3
✓ Most common adverse effects are 
diarrhoea, nausea, vomiting and 
mucocutaneous candidiasis.4
✓ Indicated for children <40 kg and 
older than 3 months; dosed at 
90/6.4 mg/kg/day in 2 divided doses.4
Mini Abridged Prescribing Information: Please refer to the full Summary of Product Characteristics (SPC) 
before prescribing. TRADE NAMES: Augmentin ES. ACTIVE INGREDIENTS: Amoxicillin (as trihydrate) 
and potassium clavulanate. PRESENTATIONS: Supplied in 100 ml glass bottle with a dosing spoon. 
INDICATIONS: Treatment of acute otitis media and community acquired pneumonia infections in children 
aged at least 3 months and less than 40 kg body weight, caused or thought likely to be caused by penicillin-
resistant Streptococcus pneumoniae. POSOLOGY & ADMINISTRATION: Oral use; recommended dose of 
90/6.4  mg/kg/day in two divided doses. CONTRAINDICATIONS: Hypersensitivity (and past history of) to 
the active substances, to any penicillins or to any of the excipients. SPECIAL WARNINGS & PRECAUTIONS: 
Before initiating therapy careful enquiry of previous hypersensitivity reactions to beta-lactams. Where 
an infection is proven to be due to an amoxicillin susceptible organism, a switch to an amoxicillin-only 
preparation should be considered. Convulsions may occur in patients receiving high doses or who have 
impaired renal function. Concomitant use of allopurinol increase likelihood of allergic skin reactions. 
Prolonged use may occasionally result in overgrowth of non-susceptible organisms. Augmentin ES contains 
aspartame (E951), a source of phenylalanine. The suspension also contains maltodextrin (glucose). Refer 
to the SPC for full list of precautions. INTERACTIONS: Penicillins may reduce the excretion of methotrexate 
causing a potential increase in toxicity. Concomitant use of probenecid is not recommended. If co-
administration with oral anticoagulants is necessary, the prothrombin time or international normalised ratio 
should be carefully monitored with the addition or withdrawal of amoxicillin. Moreover, adjustments in the 
dose of oral anticoagulants may be necessary. PREGNANCY & LACTATION: Use should be avoided unless 
considered essential by the physician. UNDESIRABLE EFFECTS: Very common (≥ 1/10): diarrhoea. Common 
(≥ 1/100, < 1/10): mucocutaneous candidosis, nausea, abdominal pain. Refer to the SPC for full list of 
undesirable effects. AUTHORISATION NUMBER: AA 1051/00101. MARKETING AUTHORISATION HOLDER: 
GlaxoSmithKline Bulgaria EOOD. LEGAL CATEGORY: POM. DATE OF PREPARATION: May 2016 In order to 
ensure that this product information reflects the most up-to-date clinical and post-marketing 
surveillance data, please always refer to the latest Summary of Product Characteristics (SPC) 
which is available from GlaxoSmithKline (Malta) Ltd (Tel: +356 21238131) REPORTING ADVERSE 
EVENTS (AEs): If you become aware of any AEs, medication errors and/or use during pregnancy 
in association with GSK products, please report the event promptly to: GSK (Malta) Limited, 1, De 
la Cruz Avenue, Qormi QRM 2458, Malta (Tel: +356 21238131) Alternatively, any suspected AEs and m 
edication errors can also be reported via the national Adverse Drug Reactions (ADRs) reporting 
system: Report forms can be downloaded from www.medicinesauthority.gov.mt/adrportal and posted 
to the Malta Medicines Authority, Post-licensing Directorate, 203, Level 3, Rue D’Argens, Gżira GŻR 1368, 
MALTA, or sent by email to postlicensing.medicinesauthority@gov.mt
MLT_GIB_AES_0001_15(3) _Augmentin_ES-Children_Advt_A4_GSKDC-PT-MLG-2016-10363_D1.indd   1 11/3/2016   6:01:51 PM
13Volume 15, 2016  issue 06
This review is partially funded through the Endeavour Scholarship Scheme.
imaging amongst others. The escalating sense of his parents’ 
desperation is depicted, and climaxes when the diagnosis is 
provided without equivocation. This is especially so given they 
were told it is a progressive and relentless disease with a bleak 
prognosis, and there was no known treatment whatsoever 
that could be provided to their son at the time. Lorenzo had 
significantly elevated VLCFAs in his blood. In the movie it 
is stated that there is a defective enzyme for metabolizing 
these fats, however this is no longer entirely correct since it is 
the peroxisomal membrane protein that is defective in ALD 
patients. The parents are told what ‘myelin’ is, and are also 
explained briefly the concept of demyelination. Distraught and 
in search for answers the father is seen reading literature on the 
pathology of adrenoleukodystrophy as well as individual case 
studies. Numerous medical terms were enlarged on screen. 
Dysphagia, seizures, spasticity, deafness, coma and death were 
amongst the words highlighted to the viewer on the screen. 
The search for a world expert on the leukodystrophies leads 
them to Professor Gus Nikolais, who was working on a diet 
for the disease. He suggests enrolling Lorenzo in a trial, and 
explains to his mother the nature of the genetic transmission of 
an X-linked disease. It was afterwards noted however that his 
VLCFAs were increasing rather than decreasing on the initially 
prescribed diet. Later during the film we see Lorenzo confined 
to a wheelchair and his family consenting for his case to be used 
as illustrative example for medical learning. This included his 
speech impairment, the visual field defects such as hemianopia 
with transient horizontal nystagmus [without optic atrophy as 
yet] as well as his characteristic gait which was illustrated when 
he was asked to walk. The Odone family was also in contact 
with the ALD Foundation where they met other families with 
members afflicted with the same disease. Later we are shown the 
Odones going through biochemistry textbooks and journals and 
drawing diagrams on their board. Michaela Odone even goes 
through Polish rat experiments on long chain fatty acid dietary 
manipulation. The first symposium on ALD was convened 
through their efforts. Loading the diet with a particular fat 
to decrease the biosynthesis of another emerged as a leading 
possibility. After administration of oleic acid, a significant drop 
in VLCFAs was noted, which eventually plateaued and did 
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not seem to improve any further. The boy’s clinical condition 
later takes an acute turn for the worse, but he miraculously 
survives the acute episode and the family look further into the 
literature, and even make a model using different paper clips 
as carbon atoms. They determine that erucic acid would be 
a better candidate therapy, however there were challenges in 
sub-fractionating this from rapeseed oil and getting it approved 
for human consumption. Finally, after obtaining the desired 
substance, they tested it out on Michaela’s sister, termed jokingly, 
‘the family rat’, and subsequently gave it to Lorenzo. The 
treatment consisted of an oil containing specific combinations 
of the triacylglycerol forms of both oleic and erucic acid [hence 
the name of the movie, Lorenzo’s oil]. Upon blood sampling and 
testing, they were contacted by the laboratory querying possible 
mislabeling of the specimen, given that the levels of the VLCFAs 
C24 and C26 were assayed twice and were within normal limits. 
This held great scientific potential, however in the setting of 
neurological damage that had already occurred. The movie ends 
on the note that the father was meeting a group of specialists 
who were looking into methods to re-myelinate ‘the shaking 
puppy dogs’, and the mother tells her child ‘if they ever give you 
back your myelin, you will be able to tell your brain to tell your 
toes … to do what you want them to do…’. The real life Lorenzo 
Odone lived up to age 30, which was significantly longer than 
originally predicted. 
Persistence and desperation leads the Odone family to 
fabricate their very own miracle. The family writes a paper to 
this effect which was described in the movie as ‘a beautiful piece 
of biochemistry’. This is another movie which shows a personal 
journey to a medical breakthrough. The author personally highly 
recommends this movie to those practicing within her medical 
discipline of chemical pathology or clinical biochemistry 
as well as those interested in the more research-based pure 
biochemistry.  
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